Skip to content

News Releases

Filter Releases
 
News Releases
Date Title and Summary View
Mar 27, 2017
-- Recently proposed merger with Molecular Templates will result in Nasdaq-listed company focused on developing novel treatments for cancer -- SOUTH SAN FRANCISCO, Calif., March 27, 2017 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today r...
Mar 17, 2017
-- Transaction to result in Nasdaq-listed company focused on developing novel treatments for cancer -- -- Molecular Templates lead drug candidate being developed to treat non-Hodgkin's Lymphoma (NHL); engineered toxin body (ETB) platform has applications in multiple oncology indications -- -- Combined company will be capitalized to support ad...
Dec 19, 2016
-- Preclinical studies will explore the effects of TH-3424 against T-cell acute lymphoblastic leukemia cancer cell lines with high AKR1C3 expression -- SOUTH SAN FRANCISCO, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer,...
Nov 15, 2016
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will be presenting at the Stifel Healthcare Conference on November 16, 2016, ...
Nov 7, 2016
-- Planning to initiate a clinical trial of evofosfamide in combination with checkpoint inhibitors -- SOUTH SAN FRANCISCO, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today reported financial results for the third qu...
Oct 25, 2016
IRVING, Texas and SOUTH SAN FRANCISCO, Calif., Oct. 25, 2016 /PRNewswire/ -- Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, and Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), a clinical-stage biopharmaceutical company specializing in the development of novel pharmaceutical products for...
Sep 29, 2016
-- Tarloxotinib Primary Interim Response Rate Endpoint Achieved in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Skin (SCCS) but not Achieved in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) or Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC); Company to Discontinue Inves...
Aug 1, 2016
-- Presented additional subset data at ASCO from Phase 3 MAESTRO trial of evofosfamide in pancreatic cancer; meaningful improvement in overall survival in patients from Asia -- SOUTH SAN FRANCISCO, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing ...
Jun 6, 2016
CHICAGO, June 06, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced multiple presentations on clinical trials on its hypoxia-activated prodrugs, evofosfamide and tarloxotinib at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3 through 7, 2016 in Chicago, Ill. Today, Thresh...
Jun 1, 2016
SOUTH SAN FRANCISCO, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in New York City on June 7, 2016 at 3:30 p.m. Eastern Time. ...
May 5, 2016
SOUTH SAN FRANCISCO, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today reported financial results for the first quarter ended March 31, 2016 and provided an update on the Company's corporate and clinical development activi...
Mar 21, 2016
SOUTH SAN FRANCISCO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, announced the appointment of Stewart M. Kroll as Chief Operating Officer. Mr. Kroll will serve as the Company's principal operating officer, will continue ...
Mar 10, 2016
-- Rights to Evofosfamide and Relevant Merck KGaA, Darmstadt, Germany Technology Returned to Threshold; Merck KGaA, Darmstadt, Germany Retains Certain Royalty and Milestone Payments Dependent Upon Successful Development and Commercialization of Evofosfamide -- -- Additional Analyses of Data from the MAESTRO Study in Pancreatic Cancer Demonstra...
Mar 1, 2016
SOUTH SAN FRANCISCO, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016, at 9:20 a.m. Eastern Time. A live webcast of...
Jan 11, 2016
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 01/11/16 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced an update on its evofosfamide program including that Threshold and Merck KGaA, Darmstadt, Germany have agreed upon key terms for the licensing back of all rights to evofosfamide to Threshold. The companies have a global license...
Dec 18, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/18/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it has initiated a significant reduction in its workforce in order to focus the company's financial resources in the near term on two ongoing Phase 2 proof-of-concept clinical trials of tarloxotinib bromide* ("tarloxotinib"...
Dec 7, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/07/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, which is being evaluated for first-line treatment of advance...
Nov 18, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/18/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the...
Nov 11, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/11/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2015 Healthcare Conference on November 17, 2015, at 1:30 p.m. Eastern Time. A live webcast of the presenta...
Nov 6, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/06/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preclinical data demonstrating that tarloxotinib bromide*, or tarloxotinib, may overcome resistance to first- and second- and third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The ...
Nov 3, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that preclinical data on the combination of evofosfamide with immune checkpoint inhibitors will be presented in a scientific poster at the Society for Immunotherapy of Cancer (SITC) annual meeting in Maryland, November 4-8, 20...
Nov 2, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/02/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter 2015. Revenue for the third quarter ended September 30, 2015 was $3.7 million. The operating loss for the third quarter ended September 30, 2015 was $6.8 million. The net loss for the thi...
Oct 27, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/27/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that it will present preclinical data on tarloxotinib bromide*, or "tarloxotinib", in two scientific posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held Novem...
Oct 13, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/13/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first two U.S. patents protecting tarloxotinib bromide*, or "tarloxotinib," the Company's proprietary hypoxia-activated, irreversible epidermal growth factor rece...
Sep 8, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/08/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Mark Hopkins, J.D., Ph.D., as Vice President of Intellectual Property and Assistant General Counsel. In this newly created position, Dr. Hopkins will oversee worldwide intellectual property strategy and acti...
Sep 3, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/03/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw Annual Global Investment Conference on September 10, 2015, at 11:15 a.m. Eastern Time. A live w...
Aug 27, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/27/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or s...
Aug 11, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/11/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company, in collaboration with the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), has initiated the first Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib" (TH-4000), for the tre...
Jul 30, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/30/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the second quarter 2015. Revenue for the second quarter ended June 30, 2015 was $3.7 million. The operating loss for the second quarter ended June 30, 2015 was $8.9 million. The net loss for the second qua...
Jul 1, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/01/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Cantor Fitzgerald Healthcare Conference on July 8, 2015, at 3:45 p.m. Eastern Time. A live webcast of the present...
May 31, 2015
CHICAGO, IL -- (Marketwired) -- 05/31/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preliminary data from the Phase 2 component of an ongoing Phase 1/2 trial of evofosfamide (an investigational compound formerly known as TH-302) in combination with the proteasome inhibitor Velcade® (bortezomib) and low-dose dexa...
May 27, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/27/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies 2015 Healthcare Conference on June 3, 2015, at 4:00 p.m. Eastern Time. A live webcast of the presentat...
May 13, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/13/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new clinical data from its ongoing Phase 2 clinical trial evaluating evofosfamide (previously known as TH-302), an investigational compound, with bortezomib (Velcade®) and dexamethasone in patients with relapsed/refr...
May 12, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/12/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's partner Merck KGaA, Darmstadt, Germany, for the development of evofosfamide (previously known as TH-302), administered in comb...
May 11, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/11/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 2015 UBS Global Healthcare Conference on May 19, 2015, at 3:30 p.m. Eastern Time. A live webcast of the presenta...
Apr 30, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/30/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the first quarter 2015. Revenue for the first quarter ended March 31, 2015 was $3.7 million. The operating loss for the first quarter ended March 31, 2015 was $9.6 million. The net loss for the first quarte...
Apr 22, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/22/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced preclinical data on TH-4000, its proprietary, molecularly-targeted, hypoxia-activated, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) suggesting that TH-4000 may overcome resistance to ther...
Apr 16, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/16/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that it will host an Analyst and Investor Day on Friday, April 24, 2015, from 11:30 AM to 1:30 PM Eastern Time in New York City. Members of Threshold's senior management team will be joined by other research and clinical lead...
Mar 19, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/19/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced it will present data on its investigational anti-cancer drugs at the annual meeting of the American Association for Cancer Research (AACR) 2015 being held April 18-22, 2015, in Philadelphia, Pennsylvania. The company will pre...
Mar 3, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/03/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2014. Revenue for the fourth quarter and year ended December 31, 2014 was $3.7 million and $14.7 million, respectively. Net loss for the fourth quarter ended...
Feb 24, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/24/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 2015 Cowen Health Care Conference on March 2, 2015, at 4:50 p.m. Eastern Time. A live webcast of the presentation...
Feb 12, 2015
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/12/15 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the pricing of an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common stock. The combined offering price of each share of com...
Dec 6, 2014
SAN FRANCISCO, CA -- (Marketwired) -- 12/06/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade®) a...
Nov 25, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/25/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 26th Annual Piper Jaffray Healthcare Conference on December 2, 2014, at 11:30 a.m. Eastern Time and at the Oppenheimer 25th ...
Nov 17, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/17/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab (Avastin®) for the treatment of glioblastoma (GBM), the most lethal fo...
Nov 11, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/11/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TH-302, an investigational anticancer drug, for the treatment of previously untreated patients with metastatic or locally advanced unresectabl...
Nov 10, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/10/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel 2014 Healthcare Conference on November, 18, 2014, at 10:20 a.m. Eastern Time. A live webcast of the presen...
Nov 6, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/06/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an ongoing Phase 1/2 trial evaluating TH-302 and low-dose dexamethasone with or without the proteasome inhibitor bortezomib (Velcade®) in patients with relapsed/refractory multiple myeloma will be prese...
Nov 3, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of TH-302 and Avastin® (bevacizumab) in patients with bevacizumab-refractory recurrent glioblastoma will be presented in two posters ...
Nov 3, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter 2014. Revenue for the third quarter ended September 30, 2014 was $3.7 million. The operating loss for the third quarter ended September 30, 2014 was $7.6 million. The net loss for the th...
Nov 3, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/03/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has completed target enrollment of 660 patients in the global Phase 3 MAESTRO (MetastAtic or unrESectable pancreaTic adenocarcin...
Sep 22, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/22/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the Independent Data Monitoring Committee (IDMC) has completed the planned interim efficacy and safety analyses of unblinded data for the Company's pivotal Phase 3 clinical trial of TH-302 in combination with doxorubicin ...
Sep 2, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/02/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014, at 10:50 a.m. Eastern Time. ...
Aug 1, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/01/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the second quarter 2014. Revenue for the second quarter ended June 30, 2014 was $3.7 million. The operating loss for the second quarter ended June 30, 2014 was $7.5 million. The net loss for the second qu...
Jul 9, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/09/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade®) and low-dose dexamethas...
Jul 1, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/01/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced initiation of a 440-patient, randomized, double-blind, placebo-controlled trial of its investigational hypoxia-activated prodrug, TH-302, in combination with pemetrexed in advanced non-squamous non-small cell lung cancer (NSCL...
May 30, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/30/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on June 5, 2014, at 10:30 a.m. Eastern Time. A live webcast of the presenta...
May 30, 2014
CHICAGO, IL -- (Marketwired) -- 05/30/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) Objective response rate of 24% (one complete response and three partial responses) in patients with recurrent glioblastoma following progression on single-agent bevacizumab Median progres...
May 30, 2014
CHICAGO, IL -- (Marketwired) -- 05/30/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) Preliminary clinical benefit rate of 31% (three partial responses and two minimal responses) in patients treated at the maximum-tolerated dose of TH-302 and low-dose dexamethasone ...
May 27, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/27/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the company will webcast its analyst event with clinical experts to be held on Sunday, June 1, 2014, from 6:00 PM to 7:30 PM Central Time at the Four Seasons Hotel Chicago. The event will include presentations highlighting...
May 14, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/14/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new clinical data from two ongoing Phase 1/2 clinical trials of its investigational hypoxia-activated prodrug, TH-302, will be presented during poster highlight sessions on Friday, May 30, 2014, at the 50th Annual Meeting ...
May 13, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/13/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the UBS Global Healthcare Conference on May 20, 2014, at 12:30 p.m. ET. A live webcast of the presentation will be ava...
May 6, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/06/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Harold E. "Barry" Selick, Ph.D., Chief Executive Officer of Threshold and Cary L. Queen, Ph.D., President of Galaxy Biotech, have been jointly named as finalists for the European Inventor Award 2014 in the "Non-European Co...
May 1, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/01/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the first quarter 2014. Revenue for the first quarter ended March 31, 2014 was $3.7 million. The operating loss for the first quarter ended March 31, 2014 was $8.6 million. The net loss for the first quarte...
Apr 3, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/03/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that results of two new preclinical studies evaluating novel combinations of TH-302, its investigational hypoxia-targeted drug, with immunotherapy, antiangiogenic therapy, and radiotherapy for the potential treatment of cancer w...
Mar 27, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/27/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its biopharmaceutical division, has initiated a Phase 1 dose escalation study assessing the safety, tolerability and anti-tumor activity of the investigational hy...
Mar 6, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/06/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in tw...
Feb 20, 2014
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/20/14 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences: 2014 RBC Capital Markets' Global Healthcare Conference, Wedne...
Dec 30, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/30/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company's pivotal Phase 3 trial of TH-302, its investigational hypoxia-targeted drug. The enrollment achievement triggers a m...
Dec 7, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that clinical data from two early-stage trials of TH-302, its investigational hypoxia-targeted drug, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place December 7 - 10, 2013,...
Dec 3, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/03/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Oppenheimer 24th Annual Healthcare Conference on December 10, 2013, at 2:10 p.m. ET. A live webcast of the present...
Nov 22, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/22/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 in combination with Avastin® (bevacizumab) in patients with recurrent glioblastoma follo...
Nov 11, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/11/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of its investigational hypoxia-targeted drug TH-302 and Avastin® (bevacizumab) in patients with recurrent glioblastoma following bevac...
Nov 7, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that clinical data on its investigational hypoxia-targeted drug, TH-302, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), December 7 - 10, 2013, in New Orleans, LA. The presentations wil...
Nov 4, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/04/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter of 2013. Revenue for the third quarter ended September 30, 2013 was $3.2 million. The operating loss for the third quarter ended September 30, 2013 was $5.2 million. The net income for the...
Oct 21, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/21/13 -- In the news release "Threshold Pharmaceuticals Announces Early Clinical Data for Combining TH-302 With Antiangiogenic Agents in Advanced Solid Tumors," issued earlier today by Threshold Pharmaceuticals (NASDAQ: THLD), we are advised by the company that the first sentence of the fifth parag...
Oct 7, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 10/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data on its investigational hypoxia-targeted drug, TH-302, will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 19 - 23, 2013, in Boston, MA. The presen...
Sep 5, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 09/05/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Stifel Healthcare Conference 2013 on September 11, 2013, at 10:55 a.m. ET. A live webcast of the presentation will ...
Aug 8, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/08/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the initiation of a Phase 2 clinical trial to evaluate the efficacy and safety of TH-302, its investigational hypoxia-targeted drug, in patients with melanoma. The study will also investigate a range of biomarkers including ser...
Aug 1, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/01/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the second quarter of 2013. Revenue for the second quarter ended June 30, 2013 was $3.2 million. The operating loss for the second quarter ended June 30, 2013 was $7.0 million. The net loss for the second ...
Jul 2, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/02/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the JMP Securities Healthcare Conference on July 10, 2013, at 3:30 p.m. ET. A live webcast of the presentation will be...
Jul 1, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/01/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced a protocol amendment to the company's pivotal Phase 3 trial of TH-302, an investigational hypoxia-targeted drug, in patients with advanced soft tissue sarcoma (STS). The changes to the protocol are based on new assumptions rela...
Jun 2, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/02/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced data from two ongoing Phase 1/2 trials evaluating TH-302, an investigational hypoxia-targeted drug, at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held in Chicago, Ill., May 31 th...
May 9, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/09/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences: BofA Merrill Lynch 2013 Healthcare Conference, May 15, 2013, ...
May 2, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/02/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the first quarter 2013. Revenue for the first quarter ended March 31, 2013 was $2.9 million. The operating loss for the first quarter ended March 31, 2013 was $6.1 million. The net loss for the first quart...
Apr 25, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/25/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 12th Annual Needham Healthcare Conference on April 30, 2013, at 1:40 p.m. ET. A live webcast of the presentation w...
Apr 1, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/01/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 20th Annual Future Leaders in the Biotechnology Industry Conference at 8:30 a.m. ET on Friday, April 5, 2013. A...
Mar 21, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/21/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced a global agreement with Siemens Healthcare to acquire its investigational agent [18F]HX4 [flortanidazole (18F)], a radiolabeled hypoxia Positron Emission Tomography (PET) tracer. [18F]HX4 could potentially be used as a companion...
Mar 7, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2012 and provided a clinical outlook related to the development of TH-302, the company's lead investigational hypoxia-targeted drug currently in pivotal Phase ...
Feb 26, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/26/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at Cowen and Company's 33rd Annual Health Care Conference at 2:10 p.m. ET on Monday, March 4, 2013. A live webcast of ...
Jan 25, 2013
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/25/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Threshold's partner Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiated the global Phase 3 MAESTRO study assessing the efficacy and safety of investigational hypoxia-targeted drug TH-302 in combina...
Dec 10, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 12/10/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Oppenheimer 23rd Annual Healthcare Conference at 3:20 p.m. ET on Thursday, December 13, 2012. A live webcast o...
Nov 15, 2012
PRAGUE, CZECH REPUBLIC -- (Marketwire) -- 11/15/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent ma...
Nov 7, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/07/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Lazard Capital Markets 9th Annual Healthcare Conference at 2:00 p.m. ET on Wednesday, November 14, 2012. A liv...
Nov 2, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/02/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the third quarter ended September 30, 2012. Revenue for the third quarter ended September 30, 2012 was $1.8 million. The operating loss for the third quarter ended September 30, 2012 was $4.0 million. The ne...
Oct 16, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/16/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the U.S. Food and Drug Administration (FDA) has reached agreement with the U.S. affiliate of Merck KGaA, Darmstadt, Germany, Threshold's partner for the development and commercialization of TH-302, covering a Special Proto...
Oct 4, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 10/04/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the 11th Annual BIO Investor Forum at 2:30 p.m. PT on October 10, 2012, taking place in San Francisco, CA. A record...
Sep 30, 2012
VIENNA, AUSTRIA -- (Marketwire) -- 09/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced preliminary data from an ongoing dose-escalation Phase 1/2 clinical trial of its investigational hypoxia-targeted drug TH-302 in combination with bevacizumab in patients with recurrent glioblastoma. No dose-limiting toxicity has been r...
Sep 26, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/26/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that clinical data on its investigational hypoxia-targeted drug, TH-302, will be highlighted in two presentations during the European Society for Medical Oncology (ESMO) 2012 Congress taking place September 28 - October 2, 2012...
Sep 19, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/19/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Charles P. Hart, Ph.D., Threshold's Vice President of Biology, will present an overview of the company's targeted tumor hypoxia platform at BIOX, Noble Financial Capital Markets' Life Sciences Exposition, to be held at the...
Sep 18, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/18/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the UBS Global Life Sciences Conference at 8:30 a.m. ET on September 19, 2012. A live webcast of the presentation w...
Sep 17, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 09/17/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that data from a randomized open-label Phase 2b clinical trial of investigational hypoxia-targeted drug TH-302 in patients with advanced pancreatic cancer will be presented at the European Society for Medical Oncology (ESMO) 201...
Aug 29, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 08/29/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that corporate presentations will be webcast during two upcoming investor meetings: Stifel Nicolaus 2012 Healthcare Conference in Boston and NewsMakers in the Biotech Industry in New York. Barry Selick, Ph.D., Thr...
Aug 16, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 08/16/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Laura G. Hansen, Ph.D., as Senior Director, Corporate Communications. In this role, Dr. Hansen is responsible for heading investor and public relations functions. Dr. Hansen brings to Threshold ...
Aug 2, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 08/02/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the second quarter ended June 30, 2012. Revenue for the second quarter ended June 30, 2012 was $1.8 million. The operating loss for the second quarter ended June 30, 2012 was $2.9 million. The net income for...
Jul 11, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/11/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Charles Hart, Vice President of Biology at Threshold, is scheduled to present at the JMP Securities Healthcare Conference on Friday, July 13, at 10:30 am Eastern time in New York City. A live webcast of ...
Jun 4, 2012
SOUTH SAN FRANCISCO, CA -- (MARKETWIRE) -- 06/04/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced details from two clinical posters featured at the American Society of Clinical Oncology Meeting in Chicago: a trial-in-progress presentation summarizing the design and status of the ongoing international Phase 3 study comparing...
May 30, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Chief Executive Officer of Threshold, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6, at 4:30 p.m. Eastern time in New York City. A live web...
May 3, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/03/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the first quarter ended March 31, 2012. Revenue for the first quarter ended March 31, 2012 was $0.3 million. The operating loss for the first quarter ended March 31, 2012 was $7.1 million. The net loss for ...
Apr 25, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/25/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Robert Simon as Senior Vice President of Regulatory Affairs. Mr. Simon will oversee Threshold's regulatory activities related to the development of TH-302, a clinical stage hypoxia-targeted cancer therapeutic...
Apr 13, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/13/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Chief Executive Officer of Threshold, is scheduled to present at the 19th Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 20, at 10:30 a.m. Eastern time in New York Ci...
Apr 11, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/11/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced it has earned a $20 million milestone payment from Merck KGaA, Darmstadt, Germany, for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled Phase 2 clinical trial ("40...
Mar 30, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) Primary progression-free survival efficacy endpoint met (p=0.005) Response rate of 27% and median PFS of 6.0 months in highest TH-302 dose group Dose-dependent TH-302-related toxicity did not increase discontinuations du...
Mar 30, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma. "Following our announcement on March 16 regarding the r...
Mar 28, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/28/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that TH-302 will be featured in four presentations, including a late-breaking clinical trial session, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on March 31 - April 4, 2012, in Chicago, IL...
Mar 16, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/16/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma. "Receiving orphan designation for TH-302 in soft tissue sarcoma in the E...
Mar 14, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/14/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the first patient has been dosed in its Phase 1/2 clinical trial of TH-302 as monotherapy and in combination with bortezomib in patients with relapsed/refractory multiple myeloma who have received at least two prior lines...
Mar 12, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/12/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) announced that TH-302 will be featured among several presentations by academic and industry experts at a symposium entitled Therapeutic and Diagnostic Modalities Targeting Hypoxia in Cancer, hosted by the New York Academy of Sciences on Wedne...
Mar 8, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/08/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2011. The net loss for the fourth quarter and year ended December 31, 2011 was $5.3 million and $25.7 million, respectively. As of December 31, 2011, Thresho...
Mar 6, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/06/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that a Late-Breaking clinical abstract has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held on March 31st - April 4th 2012, in Chicago, IL. The presentation will ...
Feb 24, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/24/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present at the 32nd Annual Cowen Health Care Conference in Boston on Tuesday, March 6, 2012 at 10:00AM EST. A live webcast of the prese...
Feb 21, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/21/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) Primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005). The combination therapy was well tolerated with a safety profile consistent with prior studies. Threshold Pharmaceu...
Feb 17, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/17/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Tillman Pearce, M.D. as its Chief Medical Officer. In this position, Dr. Pearce will oversee the development of Threshold's TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evalua...
Feb 3, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/03/12 -- Threshold Pharmaceuticals, Inc (NASDAQ: THLD) Threshold to receive $25 million upfront, plus further potential milestones and royalties Deal provides Threshold option to co-commercialize in the United States Phase 3 trial in soft tissue sarcoma on-going and randomi...
Page:
...
Next Last